Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Q4 2018 Earnings Presentation
21 slides from Precigen's earnings presentation, Feb 28, 2019
Slide 1: Fourth Quarter 2018 Business Update
Fourth Quarter 2018 Business Update 28 February 2019 Exhibit 99.2
Slide 2: Forward Looking Statements Safe Harbor Statement
Forward Looking Statements Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward
Slide 3: Financial Update
Financial Update ©2019 Intrexon Corp. All rights reserved.
Slide 4: Intrexon's Methane Bioconversion Platform
Intrexon's Methane Bioconversion Platform Methanotrophs naturally consume methane CH4 Methane CH3OH Methanol Methane oxidization enzyme CH2O Formaldehyde Methanol dehydrogenation enzyme C6H13O9P fructose-6-phosphate C3H4O3 Pyruvate CxHxOx Feedstock Product Methanotroph cell DNA Intrexon’s proprietar
Slide 5: Attractive Cost Economics for Leading Chemical – Butadiene
Attractive Cost Economics for Leading Chemical – Butadiene The vast majority of butadiene are produced as a co-product of liquid cracking through recovery from cracker C4 streams On-purpose butadiene processes include oxidative dehydrogenation of n-butane to butadiene via Dual Bed and Low Energy pro
Slide 6: Robust Microbial Production of Cannabinoids for Medical Use
Intrexon’s proprietary yeast strains enable a transformative process for robust production of cannabinoids with consistent yield and purity Platform designed to enable production of multiple target cannabinoids Robust Microbial Production of Cannabinoids for Medical Use
Slide 7: Disrupting the market: Precigen's Transformative UltraCAR-T
Disrupting the market: Precigen’s Transformative UltraCAR-T™ CAR mbIL-15 Kill Switch US FDA cleared the IND for two chimeric antigen receptor T-cell (CAR-T) therapeutic candidates utilizing our UltraCAR-T™ platform PRGN-3006 UltraCAR-T™, an investigational drug for patients with relapsed or refracto
Slide 8: UltraCAR-T Platform Brings Key Advancements to CAR-T Cell Therapy
UltraCAR-T™ Platform Brings Key Advancements to CAR-T Cell Therapy Non-viral gene transfer using multigenic vectors for expression of multiple effector genes leads to better precision and control of tumor targeting and eliminates the need for virus Sustained persistence and desired phenotype of infu
Slide 9: World's First Triple Gene Drug to Target Heart Failure in Clinic
We are continuing patient enrollment and dosing in Phase I trial of INXN-4001, the world’s first triple gene drug candidate to target heart failure, the leading cause of death in humans World’s First Triple Gene Drug to Target Heart Failure in Clinic Angiogenesis Cell Homing Immunomodulation Scar Re
Slide 10: Preliminary Data Suggests Improvements in Cardiac Performance
Preliminary Data Suggests Improvements in Cardiac Performance Characteristic Subject 01-01 Subject 01-03 Subject 01-04 Baseline 10% 10% 10% 90 Days 20% 15% 35% 6 months 20% - 40% Left Ventricular Ejection Fraction (LVEF) LVEF refers to the amount of blood being pumped out of the left ventricle each
Slide 11: ActoBiotics: AG019, AG013 and AG017 Programs
AG019 Ib/IIa trial in the treatment of early onset type 1 diabetes is ongoing and patient enrollment is proceeding in the US and Europe Collaborator Oragenics, Inc. continues patient enrollment in the Phase IIb trial for AG013 in the treatment for oral mucositis ANTIGEN-SPECIFIC TREGS MIGRATE TO INF
Slide 12: Non-browning Arctic Apples Available in Select Markets
Non-browning Arctic® Apples Available in Select Markets Okanagan Specialty Fruits’ (OSF) picked more than 2,100 bins of Arctic® apples in the 2018 harvest Select retailers are now selling fresh Arctic® sliced apples and ApBitz™ dehydrated apple snacks. ApBitz™ are also available on Amazon.com OSF is
Slide 13: Bovine Embryos – Elite Bovine Genetics Technology
Bovine Embryos – Elite Bovine Genetics Technology Trans Ova Genetics is the preeminent leader of bovine genetics in North America: Focus on continuing to expand and improve herd genetics in support of embryo sales More than 575 heifers were added in the last year, with two Jersey heifers ranking #2
Slide 14: Advancing Swine Models for Research and Regenerative Medicine
Advancing Swine Models for Research and Regenerative Medicine Exemplar Genetics is developing porcine research models, which more accurately replicate human pathology as compared to traditional research models Demand for the MiniSwine Models continues to grow Expansion into regenerative medicine con
Slide 15: Black Soldier Fly Larvae Commercial Facility is Operational
Maysville commercial facility EnviroFlight’s black soldier fly (BSF) larvae holds considerable promise as an environmentally-friendly toxin-free, sustainable source of high-value nutrients for animal feed The largest black soldier fly larvae facility in the US opened in November 2018 Ability to prod
Slide 16: AquAdvantage Approach for Sustainable Aquaculture
AquAdvantage® Approach for Sustainable Aquaculture AquAdvantage® approach enables salmon to grow to market weight in half the time with less feed in land based systems AquaBounty Technologies, Inc. (NASDAQ: AQB) is Intrexon’s majority-owned subsidiary that pioneered the AquAdvantage® solution AquAdv
Slide 17: Improved Sustainability in Tilapia Production
Improved Sustainability in Tilapia Production Tilapia forecasted to be one of the highest growth production segments in aquaculture Gene edited tilapia line, FLT 01, exempt from GM regulation according to Argentina’s National Advisory Commission on Agricultural Biotechnology (CONABIA) FLT-01 demonst
Slide 18: Next-gen Friendly Mosquitoes for Vector Control
Targeted species-specific method to suppress wild populations of disease-carrying mosquito species Next-gen Friendly™ Mosquitoes for Vector Control Transitioning to 2nd generation self-limiting, male-selecting OX5034 Friendly™ Aedes mosquito: Better economics than prior strains, without need for lar
Slide 19: Botticelli Next Gen Tissue Culture Technology
Proprietary non-GMO tissue culture technology designed to enable rapid production of clean plants with product consistency and reduced phytosanitary risk Botticelli™ Next Gen Tissue Culture Technology Potential to enable: Rapid multiplication of proprietary lines (e.g., cannabis, lettuce, tomato) Hi
Slide 20: Intrexon Overview
Diverse areas of expertise (investments across categories) Addressing real world challenges (solving unmet needs) Robust pipeline at various life stages (hedge against timing) World-first milestones (category defining solutions) Best and brightest scientists & engineers (most valued asset) Developin
Slide 21: Q&A
Q&A ©2019 Intrexon Corp. All rights reserved.